ELI LILLY & Co

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products across a single operating segment. Its portfolio spans therapeutic treatments in cardiometabolic health, oncology, immunology, and neuroscience, addressing conditions such as diabetes, obesity, various cancers, and autoimmune disorders. The company provides its therapies to patients globally, distributing primarily through wholesale distributors, retail pharmacies, and hospitals, while engaging directly with healthcare professionals and consumers via platforms such as LillyDirect.

The enterprise operates manufacturing and distribution facilities across the United States, Puerto Rico, Europe, and Asia. It markets and commercializes its medical therapies in approximately 90 countries worldwide. The company traces its origins to Indianapolis, Indiana, where its predecessor drug manufacturing business was initially established and where its corporate headquarters remain situated.

Summary of the business section of Eli Lilly's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“At the end of 2025, we employed approximately 50,000 people, including approximately 27,000 employees outside the U.S.”